Skip to Content

Octreotide Injection

Last Updated: April 30, 2020
Status: Current

Products Affected - Description
    • Octreotide Acetate injection, Hikma, 100 mcg/mL, 1 mL vial, 10 count, NDC 00641-6175-10
    • Octreotide Acetate injection, Hikma, 50 mcg/mL, 1 mL vial, 10 count, NDC 00641-6174-10
    • Octreotide Acetate injection, Hikma, 500 mcg/mL, 1 mL vial, 10 count, NDC 00641-6176-10
    • Octreotide Acetate injection, Sagent, 100 mcg/mL, 1 mL vial, 10 count, NDC 25021-0452-01
    • Octreotide Acetate injection, Sagent, 1000 mcg/mL, 5 mL vial, 1 count, NDC 25021-0455-05
    • Octreotide Acetate injection, Sagent, 50 mcg/mL, 1 mL vial, 10 count, NDC 25021-0451-01
    • Octreotide Acetate injection, Sagent, 500 mcg/mL, 1 mL vial, 10 count, NDC 25021-0453-01
    • Octreotide Acetate injection, Teva, 100 mcg/mL, 1 mL vial, 25 count, NDC 00703-3311-04
    • Octreotide Acetate injection, Teva, 1000 mcg/mL, 5 mL vial, 1 count, NDC 00703-3343-01
    • Octreotide Acetate injection, Teva, 200 mcg/mL, 5 mL vial, 1 count, NDC 00703-3333-01
    • Octreotide Acetate injection, Teva, 50 mcg/mL, 1 mL vial, 25 count, NDC 00703-3301-04
Reason for the Shortage
    • Fresenius Kabi did not provide a reason for the shortage.
    • Hikma did not provide a reason for the shortage.
    • Mylan Institutional has octreotide available.
    • Sagent has octreotide on shortage due to manufacturing delay.
    • Sun Pharma is not currently marketing octreotide.
    • Teva did not provide a reason for the shortage.
    • Novartis has Sandostatin available. The 200 mcg/mL 5 mL vials were discontinued in early-2018.
Available Products
    • Sandostatin injection, Novartis, 100 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0181-01
    • Sandostatin injection, Novartis, 50 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0180-01
    • Sandostatin injection, Novartis, 500 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0182-01
    • Octreotide Acetate injection, Fresenius Kabi, 100 mcg/mL, 1 mL vial, 10 count, NDC 63323-0376-01
    • Octreotide Acetate injection, Fresenius Kabi, 1000 mcg/mL, 5 mL vial, 1 count, NDC 63323-0379-05
    • Octreotide Acetate injection, Fresenius Kabi, 200 mcg/mL, 5 mL vial, 1 count, NDC 63323-0378-05
    • Octreotide Acetate injection, Fresenius Kabi, 50 mcg/mL, 1 mL vial, 10 count, NDC 63323-0365-01
    • Octreotide Acetate injection, Fresenius Kabi, 500 mcg/mL, 1 mL vial, 10 count, NDC 63323-0377-01
    • Octreotide Acetate injection, Hikma, 1,000 mcg/mL, 5 mL multiple dose vial, 1 count, NDC 00641-6178-10
    • Octreotide Acetate injection, Hikma, 200 mcg/mL, 5 mL multiple dose vial, 1 count, NDC 00641-6177-10
    • Octreotide Acetate injection, Mylan Institutional, 100 mcg/mL, 1 mL syringe, 10 count, NDC 67457-0245-01
    • Octreotide Acetate injection, Mylan Institutional, 50 mcg/mL, 1 mL syringe, 10 count, NDC 67457-0239-01
    • Octreotide Acetate injection, Mylan Institutional, 500 mcg/mL, 1 mL syringe, 10 count, NDC 67457-0246-01
    • Octreotide Acetate injection, Sagent, 200 mcg/mL, 5 mL vial, 1 count, NDC 25021-0454-05
    • Octreotide Acetate injection, Teva, 500 mcg/mL, 1 mL vial, 25 count, NDC 00703-3321-04

Estimated Resupply Dates

    • Hikma has octreotide 100 mcg/mL 1 mL vials and 500 mcg/mL 1 mL vials on back order and the company estimates a release date of late-June to early-July 2020. The 50 mcg/mL 1 mL vials are on back order and the company estimates a release date in late-October 2020.
    • Sagent has octreotide 50 mcg/mL 1 mL vials, 100 mcg/mL 1 mL vials, 500 mcg/mL 1 mL vials, and 1,000 mcg/mL 5 mL vials on back order and the company estimates a release date of January 2021.
    • Teva has octreotide 50 mcg/mL 1 mL vials, 100 mcg/mL 1 mL vials, 200 mcg/mL 5 mL vials, and 1,000 mcg/mL 5 mL vials on back order and the company estimates a release date of June 2020.

Updated

Updated April 30, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 16, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide